ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.
Puedes leer el artículo completo aquí: https://erj.ersjournals.com/content/59/5/2102006
Clinical characteristics of chronic obstructive pulmonary disease in never-smokers: A systematic review
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).
ERJ Podcast: GOLD 2023
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
Próximos Simposium de la EPOC, tabaco y prevención del 3 al 5 de mayo en Cáceres.
Los próximos 3, 4 y 5 de mayo tendrán lugar el VII Simposium Internacional de la EPOC y Tabaco y el XVII Simposium Internacional sobre prevención y tratamiento del tabaquismo.
- 769874·Bartolome R Celli et Al. Differential Diagnosis of Suspected COPD Exacerbations in the Acute Care Setting: Best Practice
- 778791·Alvar Agusti et Al. COPD: Providing the right treatment for the right patient at the right time
- 778987·Shyamali C Dharmage, et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study.
- 779175·José Luis Izquierdo, José Miguel Rodríguez, Carlos Almonacid, María Benavent, Ramón Arroyo-Espliguero, Alvar Agustí – Real-life burden of hospitalisations due to COPD exacerbations in Spain
- 779198·Bartolome R Celli, Dave Singh, Claus Vogelmeier & Alvar Agusti. New Perspectives on Chronic Obstructive Pulmonary Disease.
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imágenes obtenidas en el artículo original.